Targeted mutations of the corticotropin-releasing factor system: effects on physiology and behavior

A Contarino1, L H Gold

  • 1Dipartimento di Farmacologia e Anestesiologia, Largo Meneghetti 2, 35131, Padova, Italy. angelo.contarino@unipd.it

Neuropeptides
|October 3, 2002
PubMed

Insights

Genetic mouse models reveal corticotropin-releasing factor (CRF) system roles in behavior and physiology. Manipulating CRF function impacts the stress axis, anxiety, cognition, and feeding, aiding research into psychiatric and neuroendocrine disorders.

Area of Science:

  • Neuroscience
  • Genetics
  • Behavioral Science

Background:

  • The corticotropin-releasing factor (CRF) system is crucial for stress response and behavior.
  • Traditional methods have limitations in dissecting specific CRF pathway components.

Purpose of the Study:

  • To create and characterize genetic mouse models to investigate CRF system functions.
  • To elucidate the role of CRF in physiological and behavioral regulation.

Main Methods:

  • Genetic modification of genes encoding CRF peptide, binding protein, and receptors in mice.
  • Comprehensive characterization of anatomical, neuroendocrine, and behavioral outcomes in mutant mice.

Main Results:

  • Enhanced CRF function activated the hypothalamic-pituitary-adrenal axis, increased anxiety, altered cognition, and reduced feeding.
  • Blocked CRF function generally produced opposite effects, validating model utility.
  • These models enable detailed analysis of CRF circuitry elements.

Conclusions:

  • Genetic mouse models are powerful tools for understanding CRF system's role in normal and abnormal physiology and behavior.
  • These models facilitate research into psychiatric and neuroendocrine disorders and therapeutic development.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...